Status:
UNKNOWN
The Safety and Effectiveness of Tocilizumab in Rheumatoid Arthritis
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18-100 years
Brief Summary
The aim of this study is to investigate the safety and effectiveness of tocilizumab (Actemra®) using Chinese Rheumatology Information Platform (CRIP) on Chinese Rheumatology Data Centre (CRDC, http://...
Detailed Description
Tocilizumab (Actemra®) is a humanized monoclonal antibody targeting the human IL-6 receptor, which inhibits the binding of this cytokine to its receptor. It is the first monoclonal antibody developed ...
Eligibility Criteria
Inclusion
- Patients at least 18 years of age.
- Patients with a diagnosis of RA according to the revised (2010) ACR criteria.
- Patients per treating physician's judgment to treat with Tocilizumab.
- Signed written informed consent
Exclusion
- Patients are receiving or have received any investigational agent 4 weeks (or 5 half-lives of investigational agent, whichever is longer) prior to enrollment of this study.
- Subjects with contra-indications to Tocilizumab therapy as detailed in the label (with known hypersensitivity to Tocilizumab or accessories; or with active infections.).
Key Trial Info
Start Date :
December 27 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2022
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT04384068
Start Date
December 27 2018
End Date
January 31 2022
Last Update
May 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100005